Imagion Biosystems Ltd Extends Siemens Healthineers Breast Cancer Trial Partnership
Imagion extends Siemens Healthineers partnership as MagSense® breast cancer trial nears launch
Imagion Biosystems (ASX: IBX) has renewed and extended its existing Collaboration Agreement with Siemens Healthineers to support the MagSense® HER2 Breast Cancer Phase 1b/2 clinical trial. The extension arrives as the company prepares to initiate the recently cleared trial, anchoring the partnership to a meaningful stage of clinical progression.
Siemens Healthineers, described by Imagion as a global leader in MRI technology, will provide in-kind contributions of expertise and technical support rather than any disclosed cash payment. Aligning with a major MRI manufacturer offers external validation of the technology and supports the practical execution of the trial.
When big ASX news breaks, our subscribers know first
What the renewed collaboration delivers
The renewed agreement sets out a defined scope of support from Siemens Healthineers across the Phase 1b/2 trial. Rather than a financial commitment, the collaboration centres on technical and clinical expertise applied directly at the trial level.
Key elements of the collaboration include:
- In-kind contributions of expertise and limited technical support to clinical sites
- Optimisation of MRI protocols alongside Imagion’s clinical advisors and investigators
- Integration of advanced quantitative imaging techniques developed during the company’s research collaboration with Wayne State University
- Clinical site training
These techniques are expected to deliver improved image quality even at lower doses of the MagSense® imaging agent, while reducing imaging time for better clinical workflow. Imagion also anticipates that the combination of these imaging techniques and the imaging agent could enable the future development of AI diagnostic and image interpretation tools.
For investors, efficiency gains of this nature strengthen both the clinical and commercial case for the technology, potentially lowering barriers to adoption if the trial progresses as planned.
Understanding MagSense®: molecular imaging for MRI
MRI contrast agents have historically been general-purpose. They improve image resolution by creating contrast at tissue boundaries or within tissue, but they lack the molecular specificity required to make a concrete diagnosis. This limitation can leave clinicians unable to distinguish benign growths from malignant cancer using imaging alone.
MagSense® is designed to address this gap. Imagion describes it as a “first-of-its-kind molecular imaging solution for MRI” and “the first imaging technology to use targeted magnetic nanoparticles” to tag and detect cancers. Critically, the technology does not rely on ionising radiation or radioactive tracers.
Molecular specificity of this kind could carry meaningful diagnostic value. According to the company, the technology could reduce unnecessary biopsies and support earlier, better-informed treatment decisions, addressing a substantial diagnostic imaging market.
From Phase 1 success to Phase 1b/2: the clinical roadmap
The extended partnership builds on established continuity. Siemens Healthineers also supported the successfully completed Phase 1 study, giving the collaboration a track record ahead of the next stage.
FDA clearance for the Phase 1b/2 trial was issued following a Study May Proceed Notice on Imagion’s IND application, with patient recruitment now anticipated to commence in Q3 2026 across multiple contracted clinical sites.
In that Phase 1 study, a panel of independent radiologists confirmed that the MagSense® HER2 Imaging Agent produced a readily identifiable change in MRI images, differentiating between tumour-involved nodes and non-involved nodes.
The Phase 1b/2 trial is designed to establish:
- The optimised dose of the imaging agent
- The optimum imaging timing
- Accumulation of data for diagnostic performance
Imagion describes entering a Phase 1b/2 trial as “a significant milestone,” providing multiple data outputs as the MagSense® technology progresses towards commercialisation.
Ward Detwiler, President of Imagion’s U.S. operating subsidiary
“We are very appreciative of the collaboration with Siemens Healthineers and grateful for their continued interest in the MagSense® technology. Having the expertise and support of the world’s leading MRI manufacturer not only helps position us for success but also underscores the importance of molecular MRI to the broader diagnostic imaging market.”
The next major ASX story will hit our subscribers first
Pipeline and what comes next
The collaboration is expected to continue beyond breast cancer as additional pipeline candidates progress. Imagion has identified further agents targeting prostate and ovarian cancers, which could advance into IND-enabling studies as resources become available. The company has not indicated these programmes are funded or scheduled, and their progression remains subject to resourcing.
| Indication | Cancer Type | Development Stage | Siemens Support | Notes |
|---|---|---|---|---|
| HER2+ Breast Cancer | Nodal metastases | Advancing into Phase 1b/2 (Phase 1 complete) | Yes | Lead product |
| Prostate Cancer | Identified candidate | Pre-IND / IND-enabling (subject to resources) | Expected | Pipeline extension |
| Ovarian Cancer | Identified candidate | Pre-IND / IND-enabling (subject to resources) | Expected | Pipeline extension |
The extended agreement keeps a recognised MRI manufacturer engaged across Imagion’s development programme, providing continuity of technical support as the lead breast cancer trial moves towards its next stage.
Investors exploring the financial runway behind the Phase 1b/2 programme can read our full explainer on the $3.75M placement funding the trial, which details the two-tranche structure, the EGM shareholder approval requirement, and the share pricing terms including the attached IBXO listed options.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market on biotech and healthcare developments. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.